ERBB2 and breast carcinoma: We have also demonstrated that blockade of tmTNFα and sTNFα with etanercept downregulates the membrane glycoprotein mucin 4 (MUC4) expression and overcomes trastuzumab de novo or acquired resistance in HER2+MUC4+ breast cancer cells and xenografts.